JP4426461B2 - 鎮静薬または抗不安薬としての効力を有する化合物をスクリーニングする方法 - Google Patents
鎮静薬または抗不安薬としての効力を有する化合物をスクリーニングする方法 Download PDFInfo
- Publication number
- JP4426461B2 JP4426461B2 JP2004554544A JP2004554544A JP4426461B2 JP 4426461 B2 JP4426461 B2 JP 4426461B2 JP 2004554544 A JP2004554544 A JP 2004554544A JP 2004554544 A JP2004554544 A JP 2004554544A JP 4426461 B2 JP4426461 B2 JP 4426461B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- gaba
- sedative
- anxiolytic
- hpa axis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/9426—GABA, i.e. gamma-amino-butyrate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Anesthesiology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
McKernan et al., Nat. Neurosci. 2000 June; 3(6); 587-92
本発明において、HPA軸の活性化が、α1-サブタイプを含むGABAA受容体を通した介入と結びつき、よって前記化合物の鎮静効果と結びつくことが見出された。
a)前記化合物を試験系に暴露する工程;および
b)HPA軸の活性に対する化合物の効果を測定する工程;
を含む。
(発明の詳細な説明)
最初の態様において、本発明は、鎮静薬または抗不安薬としての効力を有する化合物をスクリーニングする方法であって、以下の工程:
a)前記化合物を試験系に暴露する工程;および
b)HPA軸の活性に対する化合物の効果を測定する工程;
を含む、前記スクリーニング方法を提供する。
(HPA軸の活性測定)
優れたHPA軸(視床下部−下垂体−副腎軸)活性測定は、前記活性化に応答して放出されるホルモン、例えば副腎皮質刺激ホルモン(ACTH)およびグルココルチコイド(コルチコステロンまたはコルチゾールのような)の測定である。これらのホルモンは試験動物の血中、尿中および唾液中で簡単に測定することができる。さらに、視床下部におけるCRFニューロンの活性化は、前記ニューロンにおける転写活性化の活性として評価することができる(Hoffman et al., J Neuroendocriol. 2002 Apr.; 14(4); 259-68)。
(医薬調合物)
本発明による方法で同定された治療に用いるための化合物は、未加工の化合物の形態で投与することができるが、状況に応じて、生理学的に許容される塩の形態、1つ以上のアジュバント、賦形剤、担体(carriers)、緩衝剤、希釈剤および/または他の通常の薬学的補助剤と一緒になった医薬調合物で活性成分を導入するのが好ましい。
(図面の簡単な説明)
本発明を付属の図を参照してさらに説明する。
成体雄NMRIマウス(23-27 g.)をMollegaarden(デンマーク)から購入した。前記動物を動物用施設に搬入し、湿度および温度が制御された飼育室で12:12の明暗サイクルの下、実験前の少なくとも7日間、1ケージあたり5匹で飼育した。飼料および水は自由摂取させた。全ての処理はデンマークの実験動物の管理および使用に関する国際的指針(Danish National Guide for Care and Use of Laboratory animals)に従って実施した。ゾルピデムはTocris Ltd(ブリストル、イギリス)から購入し、L-838,417は特許出願公開98004559号明細書に従って合成し、5%クレモホール(Chremophor)に溶解して、10 ml/kgの容量で注射した。
Claims (8)
- 鎮静薬または抗不安薬としての効力を有するGABAA受容体モジュレーター(modulator)をスクリーニングする方法であって、
a)化合物を非ヒト試験動物に暴露する工程であって、それにより化合物が投与される工程;および
b)HPA軸の活性に対する化合物の効果を測定する工程;および
c)化合物がHPA軸を刺激する場合に、鎮静薬候補として前記化合物を選択する工程;または、
化合物がHPA軸に影響を及ぼさない場合に、抗不安薬候補として前記化合物を選択する工程、
を含む前記スクリーニング方法。 - 試験動物がマウスまたはラットである、請求項1記載の方法。
- HPA軸の活性測定を、投与後の試験動物から得た血液サンプル中の血漿コルチコステロンおよび/またはACTHレベルを測定することにより行う、請求項2記載の方法。
- c1) 化合物がHPA軸を刺激する場合に、鎮静薬候補として前記化合物を選択する:工程を含む、請求項1ないし3のいずれか1つに記載の方法。
- c2) 化合物がHPA軸に影響を及ぼさない場合に、抗不安薬候補として前記化合物を選択する:工程を含む、請求項1ないし3のいずれか1つに記載の方法。
- 請求項1ないし5のいずれか1つに記載の方法によって化合物を同定することを含む、薬剤の開発方法。
- 以下の工程:
− 請求項1ないし5のいずれか1つに記載のスクリーニング方法によって、GABA A 受容体モジュレーターを鎮静薬候補として同定する工程;および
− 鎮静薬候補として同定されたGABA A 受容体モジュレーターまたはその薬学的に許容される塩を、患者における麻酔、前麻酔(pre−anaesthesia)、筋弛緩、または鎮静を誘導するための薬剤、または熱痙攣(fever cramps)もしくはてんかん重積状態(status epilepticus)の治療、予防または緩和のための薬剤の製造に使用する工程、
を含む、鎮静薬候補として同定されたGABA A 受容体モジュレーターまたはその薬学的に許容される塩を使用する方法。 - 以下の工程:
− 請求項1ないし5のいずれか1つに記載のスクリーニング方法によって、GABA A 受容体モジュレーターを抗不安薬候補として同定する工程:および
− 抗不安薬候補として同定されたGABA A 受容体モジュレーターまたはその薬学的に許容される塩を、不安の治療、予防または緩和のための薬剤の製造に使用する工程、
を含む、抗不安薬候補として同定されたGABA A 受容体モジュレーターまたはその薬学的に許容される塩を使用する方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200201840 | 2002-11-28 | ||
PCT/EP2003/050860 WO2004048980A1 (en) | 2002-11-28 | 2003-11-21 | Method for screening for compounds as potential sedatives or anxiolytics |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006513405A JP2006513405A (ja) | 2006-04-20 |
JP4426461B2 true JP4426461B2 (ja) | 2010-03-03 |
Family
ID=32337947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004554544A Expired - Fee Related JP4426461B2 (ja) | 2002-11-28 | 2003-11-21 | 鎮静薬または抗不安薬としての効力を有する化合物をスクリーニングする方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20060013770A1 (ja) |
EP (1) | EP1567869B1 (ja) |
JP (1) | JP4426461B2 (ja) |
AT (1) | ATE371193T1 (ja) |
AU (1) | AU2003298302A1 (ja) |
DE (1) | DE60315876T2 (ja) |
WO (1) | WO2004048980A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2328414T3 (pl) * | 2008-08-29 | 2014-05-30 | Concert Pharmaceuticals Inc | Podstawione pochodne triazolo-pirydazyny |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2232416T3 (es) * | 1999-01-27 | 2005-06-01 | MERCK SHARP & DOHME LTD. | Derivados de triazolo-piridazina como ligandos para receptores gaba. |
US7674463B1 (en) * | 1999-07-15 | 2010-03-09 | Research Development Foundation | Method of inhibiting angiogenesis by administration of a corticotropin releasing factor receptor 2 agonist |
AU780829B2 (en) * | 1999-07-15 | 2005-04-21 | Research Development Foundation | Corticotropin releasing factor receptor 2 deficient mice and uses thereof |
-
2003
- 2003-11-21 EP EP03796034A patent/EP1567869B1/en not_active Expired - Lifetime
- 2003-11-21 WO PCT/EP2003/050860 patent/WO2004048980A1/en active IP Right Grant
- 2003-11-21 AU AU2003298302A patent/AU2003298302A1/en not_active Abandoned
- 2003-11-21 AT AT03796034T patent/ATE371193T1/de not_active IP Right Cessation
- 2003-11-21 JP JP2004554544A patent/JP4426461B2/ja not_active Expired - Fee Related
- 2003-11-21 DE DE60315876T patent/DE60315876T2/de not_active Expired - Lifetime
- 2003-11-21 US US10/535,709 patent/US20060013770A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1567869A1 (en) | 2005-08-31 |
ATE371193T1 (de) | 2007-09-15 |
DE60315876T2 (de) | 2008-05-21 |
US20060013770A1 (en) | 2006-01-19 |
WO2004048980A1 (en) | 2004-06-10 |
AU2003298302A1 (en) | 2004-06-18 |
DE60315876D1 (de) | 2007-10-04 |
JP2006513405A (ja) | 2006-04-20 |
EP1567869B1 (en) | 2007-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fish et al. | Alcohol, allopregnanolone and aggression in mice | |
Stemmelin et al. | Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415 | |
Gioanni et al. | Nicotinic receptors in the rat prefrontal cortex: increase in glutamate release and facilitation of mediodorsal thalamo‐cortical transmission | |
Will et al. | Uncontrollable stress potentiates morphine’s rewarding properties | |
Simms et al. | Mifepristone in the central nucleus of the amygdala reduces yohimbine stress-induced reinstatement of ethanol-seeking | |
Roozendaal et al. | Glucocorticoids interact with the basolateral amygdala β‐adrenoceptor–cAMP/cAMP/PKA system in influencing memory consolidation | |
Valentino et al. | Pontine regulation of pelvic viscera: pharmacological target for pelvic visceral dysfunctions | |
Wessells et al. | Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study | |
Banjanin et al. | Prenatal glucocorticoid exposure alters hypothalamic–pituitary–adrenal function and blood pressure in mature male guinea pigs | |
Lee et al. | Acupuncture Stimulation Alleviates Corticosterone‐Induced Impairments of Spatial Memory and Cholinergic Neurons in Rats | |
Turkmen et al. | 3β‐20β‐dihydroxy‐5α‐pregnane (UC1011) antagonism of the GABA potentiation and the learning impairment induced in rats by allopregnanolone | |
Bonansco et al. | Neonatal exposure to oestradiol increases dopaminergic transmission in nucleus accumbens and morphine‐induced conditioned place preference in adult female rats | |
Anderzhanova et al. | The stress susceptibility factor FKBP51 controls S-ketamine-evoked release of mBDNF in the prefrontal cortex of mice | |
Friesenecker et al. | Arteriolar vasoconstrictive response: comparing the effects of arginine vasopressin and norepinephrine | |
Yoshimoto et al. | Hypothalamic circuit regulating colonic transit following chronic stress in rats | |
Bustamante-García et al. | Anxiolytic-like effects of a new 1-N substituted analog of melatonin in pinealectomized rats | |
Farrell et al. | Long-term effects of pubertal anabolic–androgenic steroid exposure on reproductive and aggressive behaviors in male rats | |
Dimitrov et al. | Tuberoinfundibular peptide of 39 residues (TIP39) signaling modulates acute and tonic nociception | |
Hamann et al. | Alterations of M1 and M4 acetylcholine receptors in the genetically dystonic (dtsz) hamster and moderate antidystonic efficacy of M1 and M4 anticholinergics | |
Rowe et al. | Antidepressants restore hypothalamic-pituitary-adrenal feedback function in aged, cognitively-impaired rats | |
Vargas et al. | Diazepam increases the hypothalamic‐pituitary‐adrenocortical (HPA) axis activity by a cyclic AMP‐dependent mechanism | |
Choi et al. | Modulation of neuropathic pain by glial regulation in the insular cortex of rats | |
Van Den Buuse et al. | Effect of adrenalectomy and corticosterone replacement on prepulse inhibition and locomotor activity in mice | |
Kiso et al. | Analgesic effects of ASP 3662, a novel 11β‐hydroxysteroid dehydrogenase 1 inhibitor, in rat models of neuropathic and dysfunctional pain | |
Griebel et al. | Characterization of the profile of neurokinin-2 and neurotensin receptor antagonists in the mouse defense test battery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061025 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20090529 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090714 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091013 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20091201 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091210 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121218 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |